The expansion of Tmhe Insurance and Pension Commission's (IPEC's) authority over medical aid societies may look like a victory for consumer protection. But if medical aid societies are stripped of the very tools they use to secure affordable care for their members, the regulator may inherit responsibility without the practical means to deliver on it.
On April 24, 2026, Zimbabwe gazetted the Insurance and Pensions Commission Amendment Act, 2026, bringing medical aid societies under the registration and supervisory authority of the Insurance and Pensions Commission (IPEC). The change significantly broadens IPEC’s reach: it must now register medical aid societies and monitor, regulate, and supervise their operations, as well as those of their associates and subsidiaries. At face value, this appears to be a long-overdue consolidation of oversight in the name of fairness, accountability, transparency, and the protection of policyholders. But law on paper and protection in practice are not the same thing.
The contradiction is hard to miss. Just as IPEC is being handed an expanded consumer-protection mandate, the Ministry of Health and Child Care is pursuing amendments to the Medical Aid Societies Regulations that would reportedly bar medical aid societies from owning or operating healthcare facilities. If that proposal passes, it would force societies to divest from clinics, hospitals, pharmacies, and laboratories that many of them established not as vanity projects, but as practical buffers against tariff shocks, service denials, and volatile private-sector pricing.
IPEC’s core duty is to protect policyholders’ interests. Yet in the medical aid space, policyholder protection is not an abstract slogan. It depends on whether a member can actually obtain treatment without ruinous shortfalls, endless pre-authorisation disputes, or the humiliation of being turned away in favour of cash patients. For many schemes, ownership or control of care delivery units has been one of the few ways to guarantee access, stabilise charges, and keep some measure of discipline in a chaotic tariff environment. Remove those units, and the regulator may be left supervising a market it cannot meaningfully tame.
The tariff question is central. No regulator can credibly claim to protect policyholders if prices remain opaque, inconsistent, and detached from the contribution base that members and employers can realistically sustain. Medical aid societies collect finite contributions, but they purchase care in a provider market where tariffs can escalate rapidly and unpredictably. In that setting, vertically integrated facilities are not merely assets on a balance sheet; they are part of the sector’s cost-containment architecture. They offer leverage, benchmark pricing, continuity of care, and a fallback option when independent providers demand upfront cash or impose unaffordable top-up fees.
IPEC’s challenge in medical aid is also fundamentally different from the one it faces in traditional insurance and pensions. In those sectors, the regulator is usually dealing with defined contractual obligations: a contribution is made, a policy is taken out, and when the insured event occurs or the benefit matures, the insurer or pension fund is expected to pay what was agreed. Medical aid does not work that way. When a member falls sick, there is no fixed or universally accepted amount that the society must pay, because the cost is largely determined by the service provider. One general practitioner may charge one fee for a consultation while another charges more for the same visit. Specialists price differently for similar procedures. Hospitals and clinics charge different admission rates for comparable care. That leaves IPEC confronting the central question at the heart of policyholder protection: in a market with no stable tariff discipline, which of these competing prices is the medical aid society supposed to honour as the fair and proper benefit payable to the member?
Keep Reading
- In Full: Nineteenth post-cabinet press briefing: July 05, 2022
- UK based Zimbabwean divorces wife of 33 years over conjugal rights
- New perspectives: Money laundering red flags in insurance sector
- 3 000 non-resident pensioners owed US$1.5 million, says Ipec
If those facilities disappear without a credible tariff framework replacing them, the consequences are foreseeable. Premiums will come under further pressure. Shortfalls will rise. Members will discover that being covered is not the same as being able to access care. Schemes will have less room to negotiate with independent providers and less ability to shield members from inflationary billing. And IPEC, newly armed with statutory authority, will then be expected to answer for outcomes that are driven not only by governance failures inside schemes, but by a structurally unbalanced healthcare market outside them.
Seen in that light, the clearest commercial winners of the proposed amendment would be private healthcare practitioners and independent facilities. Once medical aid societies are stripped of their own service-delivery units, private providers would face far less countervailing pressure in setting prices. General practitioners, specialists, hospitals, and diagnostic centres would be free to impose whatever tariffs the market can bear, knowing that schemes would have fewer alternatives and less bargaining power. That may improve provider revenues, but it is difficult to see how it advances the interests of the policyholder. If the reform weakens the only structures that currently restrain pricing and guarantee access, then it risks protecting provider income far more effectively than it protects the member who must ultimately rely on medical aid when illness strikes.
The answer to the perceived abuse of the integrated care model is regulation, not blunt prohibition. If policymakers are serious about protecting patients, they should focus on transparent tariffs, disclosure rules, governance safeguards, related-party oversight, service-quality standards, and fair competition rules that prevent self-dealing while preserving access. Banning ownership outright may produce the appearance of reform while worsening the lived reality of care.
In other words, IPEC may be receiving not a strengthened mandate, but a burden designed to fail. A regulator cannot protect policyholders in name while the system strips away the mechanisms that make affordability and access possible in practice. For IPEC to succeed, it must align regulatory reform with healthcare market realities: preserve or carefully regulate the facilities that secure member access, establish rational and enforceable tariffs, and punish abuse wherever it occurs. Anything less would leave IPEC holding responsibility for policyholder welfare without the tools needed to defend it.
The way forward is therefore not difficult to sketch. First, government and regulators should establish a transparent, consultative tariff framework that sets reasonable benchmarks for common consultations, procedures, admissions, medicines, and diagnostics, so that members, providers, and schemes are working from the same price logic. Second, medical aid societies that own or operate healthcare facilities should not be forced out of those investments indiscriminately; instead, they should be allowed to continue under strict governance rules, ring-fencing requirements, related-party disclosure obligations, and regular quality and pricing audits. Third, IPEC should be given a clear role in claims oversight, dispute resolution, and policyholder complaints so that members have a practical avenue for redress when benefits are unfairly limited or provider charges become exploitative. Above all, the Ministry of Health and Child Care and IPEC must align their reforms, because consumer protection in medical aid will only be credible if regulation of schemes is matched by regulation of the costs that drive what members ultimately receive.